Due to the lack of specific molecular targets in TNBC and increased resistance to the anti-HER2 therapies in HER2+ breast tumors, cytotoxic chemotherapy is the common alternative for treating these two most resistant subtypes of BC. This evidence concerns the gene ERBB2 and breast cancer.